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Introduction {#sec1}
============

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder that results from upper and lower motor neuron loss, leading to muscle wasting, atrophy, and, ultimately, death most often due to respiratory failure ([@bib7]). Treatment options for ALS patients are severely limited, but gene therapy approaches hold great promise ([@bib39]). ALS is thought to manifest through a multi-step process encompassing additive effects from genetic predispositions and environmental insults ([@bib1]); however, ∼10% of cases show clear monogenic heritability (familial ALS \[fALS\]), while known causative genetic mutations underlie ∼68% of fALS and ∼11% of the remaining sporadic cases of ALS ([@bib30]). Mutations in numerous genes are linked to the disease, the four most common of which, in ascending order, are dominant mutations in fused in sarcoma (*FUS*), transactive-region DNA-binding protein (*TARDBP* encoding TDP-43), superoxide dismutase 1 (*SOD1*), and large, intronic hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (*C9orf72*) ([@bib7]).

Many genes associated with ALS encode proteins important in all cells, and as such, it remains unknown why motor neurons and certain brain regions, such as the frontotemporal cortex, are selectively affected. Nonetheless, impairments in cytoskeletal dynamics and axonal transport are emerging as a central theme based on ALS-linked gene function ([@bib8], [@bib10], [@bib35]). Axonal transport is the fundamental, bi-directional process whereby cargoes (e.g., organelles and proteins) are actively transported from one end of an axon to the other, along polarized microtubules ([@bib25]). Anterograde transport, which is from the cell body to axon terminal, is dependent on the kinesin family of molecular motors, while the cytoplasmic dynein complex is responsible for retrograde axonal transport in the opposite direction. Patient post-mortem studies provided the first evidence for involvement of impaired transport in ALS, which has since been consolidated by results from a plethora of disease models implicating various cargoes ([@bib10]). Transport deficits have been linked to all four major ALS genes through *in vitro*, *ex vivo*, and *Drosophila melanogaster* experiments; however, these experimental models do not necessarily replicate the complex environment found in mammals, which is required for efficient, rapid axonal transport ([@bib34]). *In vivo* results from mammals in which individual cargoes are tracked in real time, rather than en masse, have been generated in SOD1^G93A^ and TDP-43^A315T^ ALS mice ([Table S1](#mmc1){ref-type="supplementary-material"}; [@bib5], [@bib14], [@bib18], [@bib26]). Axonal transport is disrupted in both models at early disease stages, consistent with a potential causative role in neuromuscular dysfunction and motor neuron degeneration; nonetheless, it is unclear whether these ALS mice, which express disease-causing mutant proteins at supra-physiological levels, are reflective of the full disease spectrum.

We have thus performed pseudolongitudinal assessments of *in vivo* axonal transport in two recently engineered mouse models of ALS with mutations in genes encoding DNA/RNA-binding proteins instrumental to RNA processing, TDP-43 ([@bib19]) and Fus ([@bib13]). Transgenic TDP-43^M337V^ and humanized, knockin Fus^Δ14/+^ mice, which both express mutant protein at physiologically relevant levels, have been used to address the importance of altered axonal transport to ALS neuropathology. Although mitochondria are the most frequently analyzed axonal cargo, in this study we opted to assess the trafficking of signaling endosomes, which are essential to the long-range delivery of signals critical to neuronal survival.

Results {#sec2}
=======

Imaging *In Vivo* Axonal Transport in Motor Neurons {#sec2.1}
---------------------------------------------------

To assess *in vivo* dynamics of axonal transport, we used a fluorescently labeled, binding fragment of tetanus neurotoxin (H~C~T), which is retrogradely transported along axons within neurotrophin-containing signaling endosomes toward neuronal cell bodies ([@bib37], [@bib40]). Impairments in long-range neurotrophic signaling have been implicated in several neurodegenerative conditions, including ALS ([@bib6], [@bib35]). By injecting H~C~T into the gastrocnemius and tibialis anterior muscles of the lower leg, and exposing the sciatic nerve at mid-thigh level 4--8 h post-injection, individual, fluorescently labeled endosomes being retrogradely transported can be imaged and tracked in the peripheral nerve axons of live, anesthetized mice ([Figure S1](#mmc1){ref-type="supplementary-material"}A; [@bib17]; J.N.S., A.P.T., and G.S., unpublished data).

Post-intramuscular injection, about 80% of H~C~T-positive (H~C~T^+^) axons stain for choline acetyltransferase (ChAT) ([@bib5]), suggesting that the probe is preferentially transported in motor neurons. Nevertheless, assessing transport in a mixed motor and sensory population may weaken the ability to identify motor-specific trafficking perturbations. Therefore, before analyzing transport in ALS mice, we compared endosome dynamics in motor versus sensory neurons using ChAT-eGFP mice, which permit visual differentiation of peripheral nerve types because motor axons are specifically labeled with eGFP ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Mean endosome transport speeds were greater in ChAT^+^ motor neurons compared with ChAT^−^ sensory neurons ([Figures 1](#fig1){ref-type="fig"}A and 1B), and this was not due to major pausing differences ([Figures 1](#fig1){ref-type="fig"}C and 1D). Interestingly, motor axons had clearly larger calibers than sensory axons ([Figure 1](#fig1){ref-type="fig"}E), suggesting that by imaging thicker axons, H~C~T transport can be measured in motor neurons with greater certainty than if randomly selecting an axon (i.e., \>80%; [@bib5]). To confirm this, transport dynamics were compared between ChAT^+^ axons and thicker axons from non-fluorescent control mice, and no differences were observed ([Figure S1](#mmc1){ref-type="supplementary-material"}). The bell-shaped, rather than bi-modal, speed frequency distribution generated from non-fluorescent mice ([Figure S1](#mmc1){ref-type="supplementary-material"}B) indicates that *in vivo* axonal transport of endosomes can be assessed predominantly in motor neurons by selecting large-caliber axons. This approach was thus used to analyze axonal transport in ALS mice.Figure 1Retrograde Axonal Transport of Signaling Endosomes Is Faster in Motor Neurons Than Sensory Neurons(A) Speed distribution curves of signaling endosome frame-to-frame movements in motor (ChAT^+^, green) and sensory axons (ChAT^−^, gray) indicate that axonal transport is faster in motor neurons.(B) Mean (crosses), but not maximum (circles), endosome transport is faster in motor neurons when calculated per animal.(C and D) There is no difference between motor and sensory nerves in the percentage of time endosomes paused for (C) or the percentage of endosomes that paused (D).(E) H~C~T-containing axons that are ChAT^+^ have a larger caliber than ChAT^−^ axons.^∗∗∗^p \< 0.001 and NS, not significant, paired t test. n = 5. Means ± standard error of the mean (SEM) plotted for all graphs.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

*In Vivo* Axonal Transport Is Pre-symptomatically Impaired in Mutant TDP-43 Mice {#sec2.2}
--------------------------------------------------------------------------------

Recently reported transgenic TDP-43^M337V^ mice display impairments in motor function and neuromuscular junction abnormalities beginning at 9 months in homozygous mutants without motor neuron loss up to 12 months ([@bib19], [@bib45]). We therefore first assessed retrograde transport of signaling endosomes at 9 months of age in hemizygous and homozygous TDP-43^M337V^ and TDP-43^WT^ mice and non-transgenic (NTg) controls ([Figure 2](#fig2){ref-type="fig"}). The frequency histograms of frame-to-frame endosome speeds of both TDP-43^M337V/−^ and TDP-43^M337V/M337V^ animals are shifted to the left compared with NTg mice, indicative of slower transport, whereas TDP-43^WT^ transport was unaffected because it overlaps with the curve obtained using NTg controls ([Figure 2](#fig2){ref-type="fig"}A). When compared, both mutants showed a statistically significant reduction in mean endosome speed ([Figure 2](#fig2){ref-type="fig"}B), which was at least partially due to increased pausing ([Figures 2](#fig2){ref-type="fig"}C and 2D). Mutant TDP-43 mice do not show clear behavioral phenotypes at 3 months ([@bib19], [@bib45]); we therefore assessed transport at this early time point to see whether axonal transport defects precede symptom onset and thus may contribute to motor neuron pathology. Indeed, a similar deficiency in mutant TDP-43 transport was observed at 3 months, while TDP-43^WT^ transport remained unperturbed ([Figures 3](#fig3){ref-type="fig"}A--3D). Finally, to determine at what stage transport becomes affected, we assessed endosomal trafficking at 1.5 months in TDP-43^M337V/M337V^ and TDP-43^WT/WT^ mice. We found no difference between genotypes ([Figures 3](#fig3){ref-type="fig"}E--3H) or from NTg control mice (not shown). These data indicate that TDP-43^M337V^, but not TDP-43^WT^, mice display a pre-symptomatic, non-developmental *in vivo* impairment in axonal transport of signaling endosomes that manifests between 1.5 and 3 months of age ([Figure S2](#mmc1){ref-type="supplementary-material"}).Figure 2Mutant TDP Mice Display Perturbed Axonal Transport of Endosomes at 9 Months(A) Endosome frame-to-frame speed distribution curves indicate that hemizygous and homozygous TDP-43^M337V^ mice (i, iii, green) transport endosomes more slowly than control, non-transgenic (NTg) mice (white), whereas transport is unaffected in TDP-43^WT^ controls (ii, iii, purple).(B) Mean endosomal speeds (crosses) are significantly reduced in TDP-43^M337V/−^ and TDP-43^M337V/M337V^ mice, but not TDP-43^WT^ controls (p = 0.006, one-way ANOVA), while maximum speeds (circles) remained unchanged (p = 0.0891, one-way ANOVA).(C) Endosomes in mutant TDP-43^M337V^ hemizygous and homozygous mice paused for longer periods of time compared with NTg mice (p = 0.0139, one-way ANOVA).(D) TDP-43^M337V^ mice had a greater percentage of endosomes that paused (p = 0.0046, one-way ANOVA).^∗^p \< 0.05 and ^∗∗^p \< 0.01, Dunnett's multiple-comparisons test. n = 6--11. Means ± SEM are plotted for all graphs.See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.Figure 3TDP-43^M337V^ Transport Disruption Occurs between 1.5 and 3 Months(A) Endosome frame-to-frame speed distribution curves show that at 3 months TDP-43^M337V^ (i, iii, green), but not TDP-43^WT^ (ii, iii, purple), mice transport endosomes more slowly than control, non-transgenic (NTg) mice (white).(B) Mean (crosses, p = 0.004, one-way ANOVA) and maximum (circles, p = 0.0222, one-way ANOVA) endosomal speeds are significantly reduced in TDP-43^M337V/−^ mice.(C and D) TDP-43^M337V^ hemizygotes and homozygotes show increased endosome pausing as assessed by calculating the percentage of time paused (C) (p = 0.0171, Kruskal-Wallis test) and the percentage of pausing endosomes (D) (p \< 0.001, one-way ANOVA).(E--H) At 1.5 months, there is no difference in endosome frame-to-frame speed distribution curves (E), average or maximum endosome transport speeds (F), the percentage of time that endosomes were paused (G), or the percentage of pausing endosomes (H) between TDP-43^M337V/M337V^ (green) and TDP-43^WT/WT^ (purple) mice. This suggests that transport disruption occurs between 1.5 and 3 months. Presented 1.5 month data are not significantly different from NTg control (not shown).^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001, Dunnett's/Dunn's multiple-comparisons test. NS, not significant, unpaired t test/Mann-Whitney U test. n = 5--10. Means ± SEM are plotted for all graphs.See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Axonal Transport Remains Largely Unaffected in Mutant Fus Mice Even at Late Stages {#sec2.3}
----------------------------------------------------------------------------------

Deficient *in vivo* trafficking of signaling endosomes has now been observed in SOD1^G93A^ mice ([@bib5], [@bib18]) and the TDP-43^M337V^ model reported here. To assess whether this phenotype is common to mouse models of ALS, we assessed *in vivo* transport in knockin mutant Fus^Δ14/+^ mice. This model displays loss of neuromuscular integrity and progressive degeneration of lumbar spinal motor neurons; at 3 months, mutant Fus mice show no motor neuron loss, which becomes overt by 12 (14% reduction) and 18 (20% reduction) months of age ([@bib13]). We therefore assessed endosome transport at 3, 12, and 18 months in this ALS model ([Figure 4](#fig4){ref-type="fig"}). At 3 and 12 months, there was no significant difference in axonal kinetics of these organelles ([Figures 4](#fig4){ref-type="fig"}A--4H), and, despite an increase in pausing ([Figures 4](#fig4){ref-type="fig"}K and 4L), there was no significant change in signaling endosome mean or maximum speeds at the late disease stage of 18 months ([Figures 4](#fig4){ref-type="fig"}I and 4J). Consistent with this, no significant changes in transport were observed across time points for Fus^+/+^ or Fus^Δ14/+^ mice, although Fus mutants show a subtle, progressive, yet non-significant, decline ([Figure S3](#mmc1){ref-type="supplementary-material"}).Figure 4Fus^Δ14/+^ Mice Display a Minor Impairment in Axonal Transport of Endosomes, but Only at a Late Disease Stage(A--H) The axonal dynamics of signaling endosomes are similar between Fus^+/+^ (gray) and Fus^Δ14/+^ (red) mice at 3 months (A--D) and 12 months (E--H) of age.(I--L) At 18 months, retrograde axonal transport speed of endosomes is unaffected in Fus^Δ14/+^ mice (I and J); however, mutant Fus mice do show a significant increase in the percentage of time that endosomes pause for (K) and the percentage of endosomes that paused (L).^∗^p \< 0.05; NS, not significant, unpaired t test. n = 5--7. Means ± SEM are plotted for all graphs.See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

We have previously shown that endosome transport remains stable in wild-type mice from 1 to 13--14 months of age ([@bib33]), suggesting that a natural, aging-related decline in transport does not compound the mutant TDP-43 transport defect. To ensure that this remains true up to 18 months, we compared axonal transport in all control mice aged 3--18 months. There were no significant changes in cargo dynamics ([Figure S4](#mmc1){ref-type="supplementary-material"}), suggesting that the mild pausing defect of 18-month-old mutant Fus mice is unlikely to be a direct consequence of aging and that axonal transport of signaling endosomes remains unaltered in wild-type mice up to 18 months.

Discussion {#sec3}
==========

Here, we show that an ALS mouse model of mutant TDP-43 displays a pre-symptomatic, *in vivo* deficit in axonal transport of signaling endosomes in peripheral axons, which may contribute to motor function deficits and impaired neuromuscular integrity. This defect is specific to the M337V mutation, as TDP-43^WT^ protein, which is expressed at a similar, low level as TDP-43^M337V^ relative to endogenous mouse TDP-43 ([@bib19]), had no effect on retrograde transport rates. Counter to observations of several, but not all ([@bib19]), reported TDP-43-linked pathologies ([@bib16], [@bib44]), hemizygous and homozygous TDP-43 mutant mice show similar deficiencies in trafficking, suggesting that once a threshold level of mutant TDP-43 is present, no further transport exacerbation occurs. This may be due to the heterozygous mutant TDP-43 transport defect being caused by a loss of signaling or alterations of the axonal proteome that precipitate a maximum physiological reduction in endosome transport speeds, which cannot be further affected by additional pathological protein. Furthermore, once manifested, the transport defect does not appear to get progressively worse between 3 and 9 months, indicating that a disturbance in retrograde transport of signaling endosomes may underlie the subsequent progressive reduction in neuromuscular integrity and motor function, yet is compatible with motor neuron survival at the level of the spinal cord ([@bib19]).

Alterations in the population of sciatic nerve axons over the imaging period are unlikely to account for the different rates of TDP-43^M337V^ transport, as there is no spinal cord motor neuron loss at the time points assessed ([@bib19]). Importantly, loss of neuromuscular junction connectivity does not occur until after 3 months, once again indicating that altered sciatic nerve axon profiles do not cause the transport disruption. Furthermore, loss of motor axons does not necessarily result in impaired axonal endosome dynamics, as revealed by our experiments in the Fus^Δ14/+^ mouse, likely reflecting the robustness of our technique to accurately differentiate between motor and sensory axons. All genotypes assessed showed plentiful uptake and retrograde transport of the fluorescent probe, with no overt changes in endosome number between mutant and wild-type mice, despite endocytosis dysfunction being previously linked to both TDP-43 and FUS toxicity ([@bib24]). Moreover, heterogeneity in axonal endosome-associated Rab proteins, in particular Rab5 and Rab7, is unlikely to cause the observed transport distinctions because Rab7 is the predominant Rab associated with H~C~T-positive axonal endosomes ([@bib12]).

Nonetheless, the TDP-43^M337V^ mouse data add to the impaired mitochondrial transport reported in TDP-43^A315T^ mice and defective mitochondria and signaling endosome trafficking in SOD1^G93A^ mice ([Table S1](#mmc1){ref-type="supplementary-material"}). ALS-linked mutations in *SOD1* and *TARDBP* may thus cause early/pre-symptomatic, generalized defects in axonal transport in motor neurons (rather than cargo-specific deficits), leading to dysfunction and degeneration ([@bib19]). This may be caused by cargo-independent impairments in the cytoskeleton or motor proteins (e.g., the cytoskeletal regulator HDAC6 is a known target of TDP-43; [@bib15]), or by aberrant binding of mutant ALS proteins to motor complexes ([@bib38], [@bib47]); however, this will have to be directly confirmed in the TDP-43^M337V^ model.

Contrastingly, signaling endosome transport in Fus^Δ14/+^ mice remained largely unaffected even during latter disease stages, despite a 20% loss of spinal cord motor neurons at 18 months ([@bib13]), confirming that degenerating axons do not always have altered transport kinetics ([@bib27]). This implies that transport disturbances are not necessarily a non-specific by-product of neurodegeneration, at least during earlier disease stages, and thus emphasizes the specificity of transport defects in mutant TDP-43 and SOD1 mice. However, it remains possible that motor neuron loss proceeds very rapidly and targets only specific subpools of motor neurons in Fus^Δ14/+^ mice, such that any preceding defect in transport was missed ([@bib29]). Alternatively, mutant Fus mice may display cargo-specific (e.g., mitochondria, RNA granules) or anterograde transport defects, some of which have been reported in other ALS models ([@bib2], [@bib3]), thus additional cargoes should also be assessed in Fus^Δ14/+^ mice. Nevertheless, altogether our findings indicate that pre-symptomatic abnormalities in retrograde axonal transport of neurotrophin-containing signaling endosomes may not be common to all ALS-linked genes and that there are inherent distinctions in the pathomechanism of ALS caused by mutations in different RNA processing genes. Although TDP-43 and FUS are both RNA/DNA-binding proteins that process RNA predominantly in the nucleus, they regulate the expression and splicing of largely distinct gene sets ([@bib9], [@bib23]) and show neuropathological idiosyncrasies when mutated ([@bib4]), which could account for these discrepancies in axonal transport deficits. As could the observation that wild-type TDP-43 and SOD1 proteins consistently associate with motor neuron signaling endosomes, whereas FUS does not ([@bib11]).

Disruptions in axonal transport have been linked to the *M337V TARDBP* mutation in a range of *in vitro* and *Drosophila* larval models ([@bib2], [@bib3], [@bib42]). Although the severe frameshift *FUS* mutation modeled in Fus^Δ14/+^ mice has not previously been assessed, transport perturbations have been reported in several mutant *FUS* models, including *Drosophila* larvae ([@bib3]), isolated squid axoplasm ([@bib32]), and human motor neurons derived from induced pluripotent stem cells (iPSCs) ([@bib21]).

Why then do Fus^Δ14/+^ mice not show impaired signaling endosome transport, at least until a late disease stage? In addition to the possibilities mentioned above, there are other potential explanations. First, distinctions may arise because of the different FUS mutations being analyzed and their expression in the presence or absence of the wild-type allele. Second, although *Drosophila* is an excellent model that has provided instrumental insights into neurobiology, as well as neurological diseases ([@bib20], [@bib41], [@bib46]), *in vivo* transport analyses are conducted in larvae in which organs have been removed, so there is considerable disruption to the organism, which is being analyzed during development and is thus perhaps not the best model for age-related neurodegeneration. Moreover, the complex, long-range neurotrophin signaling program is not conserved in *Drosophila*, while mutant ALS transgenes are often overexpressed to above physiological levels, which can induce phenotypes even with wild-type FUS transgenes ([@bib3]). *In vitro* axonal transport dynamics differ from *in vivo* trafficking ([@bib5], [@bib17]), possibly because of cultured neurons lacking the complete series of necessary cellular and chemical interactions (e.g., myelination and target muscle cells in the case of motor neurons) ([@bib34]), which is particularly important for ALS as both cell- and non-cell-autonomous pathomechanisms contribute to disease onset and progression ([@bib29]). In addition to variability inherent to iPSC differentiation, it remains unknown how closely motor neuron developmental stages in culture correlate with age-related degeneration *in vivo*. By imaging axonal transport of signaling endosomes in intact sciatic nerves of anesthetized mice, we are instead certain of the disease stage and physiological environment of the peripheral axons under investigation.

In summary, we have assessed *in vivo* retrograde axonal transport of signaling endosomes in two mouse models of ALS that express disease-causing mutant proteins at near endogenous levels. Mutant TDP-43, but not mutant Fus, mice displayed a pre-symptomatic deficiency in endosome transport, suggesting that reduced neurotrophin signaling may contribute to mutant TDP-43-mediated neuropathology and that general defects in axonal transport are specific to a subset of ALS-linked genes in an *in vivo* mammalian setting.

STAR★Methods {#sec4}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Chemicals, Peptides, and Recombinant Proteins**H~C~T^441^[@bib31]N/AAlexaFluor555 C~2~ maleimideLife TechnologiesA-20346recombinant human brain-derived neurotrophic factorPeprotech450-02**Experimental Models: Organisms/Strains**Mouse: Tg(Chat-EGFP)GH293Gsat/Mmucd (ChAT-eGFP)Mutant Mouse Resource and Research CenterMMRRC: 000296-UCDMouse: B6;129S6-Gt(ROSA)26Sor^m1(TARDBP∗M337V/Ypet)Tlbt^/J (WT and M337V TDP43)The Jackson LaboratoryJAX: 029266Mouse: B6N;B6J-Fus^tm1Em*cf.*/H^ (Fus^+/+^ and Fus^Δ14/+^)[@bib13]N/A**Software and Algorithms**Tracker (Version 2.0.0.26)Kinetic Imaging Ltd.N/A

Lead Contact and Materials Availability {#sec5.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Giampietro Schiavo (<giampietro.schiavo@ucl.ac.uk>). This study did not generate new unique reagents.

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### Animals {#sec5.3.1}

All mouse handling and experiments were performed under license from the United Kingdom Home Office in accordance with the Animals (Scientific Procedures) Act (1986) and approved by the University College London -- Queen Square Institute of Neurology Ethics Committee. All mice were maintained in individually ventilated cages and on a standard diet. Tg(Chat-EGFP)GH293Gsat/Mmucd mice (MMRRC Stock Number 000296-UCD), referred to as ChAT-eGFP mice, were maintained and imaged as heterozygotes on a CD-1 background. The male to female ratio used for these experiments was 2:3. B6;129S6-Gt(ROSA)26Sor^m1(TARDBP∗M337V/Ypet)Tlbt^/J (WT and M337V TDP43, Jackson Laboratory strain \#029266, <https://www.jax.org/strain/029266>) and B6N;B6J-Fus^tm1Em*cf.*/H^ (Fus^+/+^ and Fus^Δ14/+^) mice were maintained on a C57BL/6 background and genotyped as detailed ([@bib13], [@bib19]). ChAT-eGFP mice used for motor versus sensory analyses were 79-134 days old. Non-transgenic (NTg) control and TDP43 mice sacrificed for 1.5, 3, and 9 month time points were 55-57, 102-125, and 249-71 days old, respectively. The male to female ratio used for these time points were 1:1, 2:15 and 35:6, respectively. Fus mice sacrificed for 3, 12, and 18 month time points were 104-115, 365-368, and 568-588 days old, respectively. The male to female ratio used for these time points were 4:3, 6:7 and 3:7, respectively. Littermates of either sex were pooled in all analyses because no significant differences in transport were observed between males and females independent of the genotype ([Figures S4](#mmc1){ref-type="supplementary-material"}E--S4H, and data not shown). Sample sizes of 5 or above were chosen based on two-sample, two-sided power calculations, with standard power of 0.8 (1−β) and type I error rate of 5% (α). Estimated mean and standard deviation of average signaling endosome transport speeds per animal were calculated from previous data generated from mice modeling neuromuscular diseases.

Method Details {#sec5.4}
--------------

### Axonal transport imaging {#sec5.4.1}

*In vivo* kinetics of signaling endosomes labeled with atoxic binding fragment of tetanus neurotoxin (H~C~T) were assessed as previously described ([@bib17]; J.N.S., A.P.T., and G.S., unpublished data). Briefly, H~C~T (H~C~T^441^, residues 875-1315) fused to an improved cysteine-rich tag and a human influenza haemagglutinin epitope was bacterially expressed as a glutathione-*S*-transferase fusion protein ([@bib31]), and labeled with AlexaFluor555 C~2~ maleimide (Life Technologies, A-20346). On the morning of analysis, H~C~T was pre-mixed with recombinant human brain-derived neurotrophic factor (BDNF, Peprotech, 450-02) in phosphate buffered saline. Under isofluorane-induced anesthesia and on a heat-pad to maintain body temperature, two 1-2 mm long incisions were made in the skin above the gastrocnemius and tibialis anterior muscles of the right leg. 3.5-5 μg of H~C~T with 25 ng BDNF was then injected in a volume of ≈1.5 μL per muscle into the motor end plate region as per [@bib28]. The incisions were closed by suturing and the animal allowed to fully recover. 4-8 h post-injection, animals were terminally anaesthetised using isofluorane and 1--1.5 cm of the right sciatic nerve was exposed by removal of the overlying skin and musculature. Curved forceps were then used to cautiously separate the sciatic nerve from the underlying connective tissue, such that a small piece of magic tape could be placed between the two to aid imaging. Still under anesthesia, the mouse was transferred to an inverted LSM780 laser scanning microscope (Zeiss) within an environmental chamber pre-warmed and set throughout the experiment to 37°C. The body weight of the animal and careful positioning ensures that the sciatic nerve remains stationary on the coverslip overlying the 63x Plan-Apochromat oil immersion objective lens (Zeiss). An area containing several axons retrogradely transporting the fluorescent H~C~T probe was selected and imaged every 2.4-3.2 s at 100x digital zoom (1024x1024, 1% laser power). All imaging was completed within 1 h of initiating terminal anesthesia.

### Axonal transport analysis {#sec5.4.2}

Confocal image series were converted into .avi files and individual endosome dynamics manually tracked using Tracker (Kinetic Imaging Ltd.) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Endosomes were included in the analysis if they could be observed for ≥ 5 consecutive frames and did not pause for \> 10 consecutive images. Endosomes that were tracked and then paused for long periods were not included for fear of issues associated with phototoxicity. Nevertheless, on average fewer than one endosome per animal did this and the phenotype was not linked to a particular genotype. Moreover, endosomes moving solely in the anterograde direction were also not included as they were similarly infrequent. All individual frame-to-frame step speeds are included in the presented speed frequency histograms (459.6 ± 11.4 frame-to-frame speeds per animal were calculated), meaning that an endosome tracked across 11 consecutive frames will generate 10 frame-to-frame speeds to be included in the frequency histogram. To determine the mean endosome speed per animal, the speeds of individual endosomes were calculated and then an average of these speeds determined (50.3 ± 0.8 endosomes per animal were tracked). The fastest endosome speed per animal is reported as the 'maximum speed'. All speed analyses include frames and time during which endosomes may have been paused, i.e., we report the speed across the entire tracked run length and not the speed solely when motile. An endosome was considered to have paused if it remained in the same position for two consecutive images. The '% time paused' is a calculation of the length of time all tracked endosomes remained stationary, while the '% pausing endosomes' details the proportion of endosomes that displayed at least one pause while being tracked. At least six endosomes from at least two individual, thick axons were assessed per animal.

### Axon calibre analysis {#sec5.4.3}

Axon calibres were determined from images taken for endosome transport analyses by measuring the distance between the upper and lower margins of transported fluorescent signaling endosomes orthogonally from the direction of transport. A minimum of ten measurements were made along the length of the axon to calculate average widths per axon, and three different axons per animal were used to calculate a per animal mean width.

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

Data were assumed to be normally distributed unless evidence to the contrary could be provided by the D'Agostino and Pearson omnibus normality test. Normally distributed data were statistically analyzed using a t test or one-way analysis of variance (ANOVA) with Dunnett's multiple comparisons test, and non-normally distributed data with a Mann-Whitney *U* test or Kruskal-Wallis test with Dunn's multiple comparisons test. Paired t tests were used to compare transport kinetics in ChAT^+^ versus ChAT^-^ axons as data were generated from the same animals. Endosomes were tracked from videos in which the genotype of the animal was blinded. All tests were two-tailed and an α-level of p \< 0.05 was used to determine significance. GraphPad Prism 6 software was used for all statistical analyses and figure production. All figure legends contain details of statistical tests and sample sizes (*i.e*. number of animals) used, with dispersion and precision measures.

Data and Code Availability {#sec5.6}
--------------------------

This study did not generate/analyze datasets/code.
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